Does the media prefer MGNX or PDSB?

In the previous week, PDS Biotechnology had 1 more articles in the media than MacroGenics. MarketBeat recorded 4 mentions for PDS Biotechnology and 3 mentions for MacroGenics. PDS Biotechnology's average media sentiment score of 0.56 beat MacroGenics' score of 0.40 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PDSB or EVMN more profitable?

Evommune's return on equity of -62.63% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -708.18% -136.50% Evommune N/A -62.63% -40.55%

Does the media favor KROS or PDSB?

In the previous week, Keros Therapeutics and Keros Therapeutics both had 4 articles in the media. Keros Therapeutics' average media sentiment score of 0.78 beat PDS Biotechnology's score of 0.56 indicating that Keros Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PLX or PDSB?

In the previous week, PDS Biotechnology had 3 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for PDS Biotechnology and 1 mentions for Protalix BioTherapeutics. PDS Biotechnology's average media sentiment score of 0.56 beat Protalix BioTherapeutics' score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALEC or PDSB more profitable?

PDS Biotechnology has a net margin of 0.00% compared to Alector's net margin of -850.13%. Alector's return on equity of -531.03% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Alector -850.13% -531.03% -44.00% PDS Biotechnology N/A -708.18% -136.50%

Does the media refer more to ALEC or PDSB?

In the previous week, Alector had 17 more articles in the media than PDS Biotechnology. MarketBeat recorded 21 mentions for Alector and 4 mentions for PDS Biotechnology. Alector's average media sentiment score of 0.57 beat PDS Biotechnology's score of 0.56 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 2 Very Positive mention(s) 8 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PDS Biotechnology (PDSB) Competitors

$1.38 +0.36 (+35.29%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.33 -0.05 (-3.70%)

As of 10/9/2026 07:59 PM Eastern

Compare

PDSB vs. MGNX, EVMN, KROS, PLX, and ALEC

Should you buy PDS Biotechnology stock or one of its competitors? PDS Biotechnology's main competitors and comparable companies include MacroGenics (MGNX), Evommune (EVMN), Keros Therapeutics (KROS), Protalix BioTherapeutics (PLX), and Alector (ALEC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PDS Biotechnology compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

PDS Biotechnology has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.59	-$74.62M	-$0.22	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

MacroGenics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

MacroGenics currently has a consensus price target of $6.33, suggesting a potential upside of 69.34%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 552.17%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PDS Biotechnology has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. MacroGenics' return on equity of -109.26% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
PDS Biotechnology	N/A	-708.18%	-136.50%

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 8.4% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, PDS Biotechnology had 1 more articles in the media than MacroGenics. MarketBeat recorded 4 mentions for PDS Biotechnology and 3 mentions for MacroGenics. PDS Biotechnology's average media sentiment score of 0.56 beat MacroGenics' score of 0.40 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MacroGenics and PDS Biotechnology tied by winning 7 of the 14 factors compared between the two stocks.

How does PDS Biotechnology compare to Evommune?

PDS Biotechnology (NASDAQ:PDSB) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Evommune's return on equity of -62.63% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-708.18%	-136.50%
Evommune	N/A	-62.63%	-40.55%

PDS Biotechnology presently has a consensus target price of $9.00, indicating a potential upside of 552.17%. Evommune has a consensus target price of $33.33, indicating a potential upside of 434.02%. Given PDS Biotechnology's higher possible upside, equities research analysts plainly believe PDS Biotechnology is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Evommune	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, PDS Biotechnology had 4 more articles in the media than Evommune. MarketBeat recorded 4 mentions for PDS Biotechnology and 0 mentions for Evommune. PDS Biotechnology's average media sentiment score of 0.56 beat Evommune's score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
PDS Biotechnology	Positive
Evommune	Neutral

26.8% of PDS Biotechnology shares are owned by institutional investors. 8.4% of PDS Biotechnology shares are owned by insiders. Comparatively, 31.1% of Evommune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

PDS Biotechnology has higher earnings, but lower revenue than Evommune. PDS Biotechnology is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A
Evommune	$13M	17.42	-$68.87M	-$11.03	N/A

Summary

Evommune beats PDS Biotechnology on 8 of the 14 factors compared between the two stocks.

How does PDS Biotechnology compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Keros Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 12.6% of Keros Therapeutics shares are held by insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Keros Therapeutics and Keros Therapeutics both had 4 articles in the media. Keros Therapeutics' average media sentiment score of 0.78 beat PDS Biotechnology's score of 0.56 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Keros Therapeutics presently has a consensus price target of $20.50, suggesting a potential upside of 71.55%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 552.17%. Given PDS Biotechnology's higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PDS Biotechnology has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
PDS Biotechnology	N/A	-708.18%	-136.50%

Keros Therapeutics has higher revenue and earnings than PDS Biotechnology. Keros Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.97	$87.01M	-$3.70	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

Summary

Keros Therapeutics beats PDS Biotechnology on 8 of the 13 factors compared between the two stocks.

How does PDS Biotechnology compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

PDS Biotechnology has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
PDS Biotechnology	N/A	-708.18%	-136.50%

Protalix BioTherapeutics has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, PDS Biotechnology had 3 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for PDS Biotechnology and 1 mentions for Protalix BioTherapeutics. PDS Biotechnology's average media sentiment score of 0.56 beat Protalix BioTherapeutics' score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protalix BioTherapeutics has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.78	$8.31M	$0.23	12.09
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

Protalix BioTherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 331.65%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 552.17%. Given PDS Biotechnology's higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

PDS Biotechnology beats Protalix BioTherapeutics on 9 of the 15 factors compared between the two stocks.

How does PDS Biotechnology compare to Alector?

Alector (NASDAQ:ALEC) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Alector has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

PDS Biotechnology has lower revenue, but higher earnings than Alector. PDS Biotechnology is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	11.03	-$142.93M	-$1.10	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

In the previous week, Alector had 17 more articles in the media than PDS Biotechnology. MarketBeat recorded 21 mentions for Alector and 4 mentions for PDS Biotechnology. Alector's average media sentiment score of 0.57 beat PDS Biotechnology's score of 0.56 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	2 Very Positive mention(s)	8 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.8% of Alector shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 8.3% of Alector shares are owned by insiders. Comparatively, 8.4% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PDS Biotechnology has a net margin of 0.00% compared to Alector's net margin of -850.13%. Alector's return on equity of -531.03% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
PDS Biotechnology	N/A	-708.18%	-136.50%

Alector currently has a consensus price target of $3.40, indicating a potential upside of 63.46%. PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 552.17%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Alector beats PDS Biotechnology on 8 of the 15 factors compared between the two stocks.

Get PDS Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDSB vs. The Competition

Export

Metric	PDS Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$77.24M	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-2.16	13.55	274.99	26.14
Price / Sales	N/A	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	7.67	17.17	11.22	6.33
Net Income	-$34.50M	-$22.69M	$3.50B	$382.15M
7 Day Performance	84.37%	-1.34%	-0.89%	-1.40%
1 Month Performance	367.96%	-8.04%	-4.02%	-3.35%
1 Year Performance	45.68%	14.18%	7.13%	1.49%

PDS Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDSB PDS Biotechnology	2.8979 of 5 stars	$1.38 +35.3%	$9.00 +552.2%	+45.7%	$77.24M	N/A	N/A	21	Short Interest Decrease
MGNX MacroGenics	1.7253 of 5 stars	$3.72 -1.5%	$6.33 +70.5%	+121.3%	$236.65M	$149.50M	N/A	293	News Coverage
EVMN Evommune	2.369 of 5 stars	$6.36 -4.4%	$33.33 +424.2%	N/A	$230.77M	$13M	N/A	48
KROS Keros Therapeutics	3.7342 of 5 stars	$11.27 -2.2%	$20.50 +82.0%	-23.9%	$223.55M	$15.01M	N/A	92	News Coverage Analyst Upgrade
PLX Protalix BioTherapeutics	2.3641 of 5 stars	$2.73 +0.6%	$12.00 +340.4%	+17.8%	$219.56M	$80.62M	N/A	226

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDSB) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PDS Biotechnology (PDSB) Competitors

PDSB vs. MGNX, EVMN, KROS, PLX, and ALEC

How does PDS Biotechnology compare to MacroGenics?

Summary

How does PDS Biotechnology compare to Evommune?

Summary

How does PDS Biotechnology compare to Keros Therapeutics?

Summary

How does PDS Biotechnology compare to Protalix BioTherapeutics?

Summary

How does PDS Biotechnology compare to Alector?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PDS Biotechnology (PDSB) Competitors

PDSB vs. MGNX, EVMN, KROS, PLX, and ALEC

How does PDS Biotechnology compare to MacroGenics?

Which has stronger earnings & valuation, MGNX or PDSB?

Which has more volatility and risk, MGNX or PDSB?

Do analysts recommend MGNX or PDSB?

Is MGNX or PDSB more profitable?

Do institutionals & insiders have more ownership in MGNX or PDSB?

Does the media prefer MGNX or PDSB?

Summary

How does PDS Biotechnology compare to Evommune?

Is PDSB or EVMN more profitable?

Do analysts rate PDSB or EVMN?

Does the media prefer PDSB or EVMN?

Do institutionals and insiders believe in PDSB or EVMN?

Which has preferable earnings and valuation, PDSB or EVMN?

Summary

How does PDS Biotechnology compare to Keros Therapeutics?

Which has more volatility & risk, KROS or PDSB?

Do insiders and institutionals have more ownership in KROS or PDSB?

Does the media favor KROS or PDSB?

Do analysts prefer KROS or PDSB?

Is KROS or PDSB more profitable?

Which has stronger earnings & valuation, KROS or PDSB?

Summary

How does PDS Biotechnology compare to Protalix BioTherapeutics?

Is PLX or PDSB more profitable?

Which has more volatility & risk, PLX or PDSB?

Do institutionals & insiders believe in PLX or PDSB?

Does the media favor PLX or PDSB?

Which has higher earnings and valuation, PLX or PDSB?

Do analysts rate PLX or PDSB?

Summary

How does PDS Biotechnology compare to Alector?

Which has more risk & volatility, ALEC or PDSB?

Which has better earnings and valuation, ALEC or PDSB?

Does the media refer more to ALEC or PDSB?

Do institutionals & insiders have more ownership in ALEC or PDSB?

Is ALEC or PDSB more profitable?

Do analysts recommend ALEC or PDSB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools